Cabozantinib Development Program

Discovered by Exelixis, and the focus of our development and commercialization efforts, Cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.

Download the PDF.

R & D
Pipeline Overview
Early-Stage Compounds
Cabozantinib Pipeline
Other Partnered Programs
Clinical Trials

Filter by Therapeutic Area

- Adrenal Tumors
- Adrenocortical Carcinoma
- Any GIst Tumors
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer (CRC)
- Differentiated Thyroid Cancer (DTC)
- Endometrial Cancer
- Esophageal Cancer
- Gastroesophageal Cancer
- Gastrointestinal (GI) Cancers
- Gastrointestinal Stromal Tumor (GIST)
- Gastrocaryotic (GI) Cancers
- Germ Cell Tumors
- Gynecologic Cancers
- Head and Neck Cancer
- Hepatocellular Carcinoma (HCC)
- Lung Cancer
- Melanoma
- Mesothelioma
- Neuroendocrine Tumors (NETS & Carcinoid)
- Neuroforamina
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Pediatric Cancer
- Pediatric Glioma
- Pediatric Multiple Tumor Types
- Pediatric Neuroforamina
- Pediatric Sarcoma
- Prostate Cancer
- Rare GI Tumors
- Renal Cell Carcinoma (RCC)
- Sarcoma
- Squamous Cell Carcinoma
- Thyroid Cancer
- Urothelial Carcinoma (UC)

Clear Filters

Active Sponsored Trial | Roche Sponsored Trial | Active Means Number Sponsored Trial | Investigator-Sponsored Trial | Collaboration with Roche, Including Phase 1b Program | Sponsored by the European Organisation for Research and Treatment of Cancer (EORTC)

PHASE 1 | PHASE 2 | PHASE 3

Collapse All

Genitourinary (GU) Cancers

Cabozantinib + Atezolizumab +/- CBM588 (Metastatic RCC)
- Renal Cell Cancer

CABOSTA: Cabozantinib + Ketoconazole + Nilutamide (Metastatic Hormone Sensitive Prostate Cancer)
- Prostate Cancer

Cabozantinib + Enfortumab Vedotin (Locally Advanced or Metastatic UC)
- Urothelial Carcinoma

COSMIC-021: Cabozantinib (Advanced UC)
- Urothelial Carcinoma

COSMIC-029: Cabozantinib + Atezolizumab (Advanced RCC, Advanced UC & CRPC)
- Renal Cell Carcinoma / Urothelial Carcinoma / Prostate Cancer

Cabozantinib + Nivolumab ± Ipilimumab
- Any GU Tumors

Cabozantinib + Avelumab (Metastatic Renal Cell Carcinoma)
- Renal Cell Carcinoma

Cabozantinib (Metastatic Germ Cell Tumors)
- Germ Cell Tumors

Cabozantinib (Metastatic, CRPC with Sarcoma, Metastasis)
- Prostate Cancer

Cabozantinib + Nivolumab ± Ipilimumab (Metastatic Non Clear Cell Renal Carcinoma)
- Renal Cell Carcinoma

Cyro-GEL CTT: Radiation Surgery Followed by Cabozantinib + Nivolumab (Metastatic RCC)
- Renal Cell Carcinoma

ARATE: Cabozantinib + Atezolizumab (Muscle Invasive Bladder Cancer)
- Bladder Cancer

RenCaTa: Cabozantinib + Pembrolizumab (Metastatic UC Ineligible for Cisplatin)
- Bladder Cancer / Urothelial Carcinoma

RadCarc: Cabozantinib + Radium-223 Dichloride (Advanced RCC with Bone Metastasis)
- Renal Cell Carcinoma

Cabozantinib (Advanced or Metastatic Urothelial Carcinoma)
- Urothelial Carcinoma

Cabozantinib (Clear Cell or Non Clear Cell Metastatic RCC)
- Renal Cell Carcinoma

ATLANTIS: Cabozantinib (Metastatic Urothelial Carcinoma)
- Urothelial Carcinoma

CONTACT-02: Cabozantinib + Atezolizumab vs. Nivolumab vs. Cabozantinib (First Line Advanced RCC)
- Renal Cell Carcinoma

CONTACT-03: Cabozantinib + Atezolizumab vs. Cabozantinib vs. Nivolumab + Ipilimumab (Metastatic Castrate Resistant PC)
- Prostate Cancer

COSMIC-313: Cabozantinib + Nivolumab + Ipilimumab (First Line Intermediate or Poor Risk Advanced or Metastatic RCC)
- Renal Cell Carcinoma

PRIMUS: Nivolumab + Ipilimumab Followed by Cabozantinib + Nivolumab vs. Nivolumab (First Line Metastatic RCC)
- Renal Cell Carcinoma

Gastrointestinal (GI) Cancers

Cabozantinib + Tiki-Vib (Metastatic Colorectal Adenocarcinoma)
- Colorectal Carcinoma

CABELLA: Cabozantinib + Durvalumab (Advanced CRC & HCC)
- Colorectal Cancer / Hepatocellular Carcinoma

Cabozantinib ± Nivolumab (Metastatic Liver Metastasis HCC)
- Hepatocellular Carcinoma

COSMIC-029: Cabozantinib + Atezolizumab (HCC & CRC)
- Colorectal Cancer / Hepatocellular Carcinoma

Cabozantinib + Pembrolizumab (Metastatic Pancreatic Adenocarcinoma)
- Pancreatic Cancer

Cabozantinib + Atezolizumab (Metastatic, Metastatic Pancreatic Cancer)
- Pancreatic Cancer

Cabozantinib + Nivolumab (Unresectable Hepatocellular Carcinoma (Sub-CRC)
- Colorectal Carcinoma

Cabozantinib + Nivolumab/Ipilimumab and Nivolumab (Hepatocellular Carcinoma)
- Hepatocellular Carcinoma

Cabozantinib (Advanced Hepatocellular Carcinoma with Child Pugh Class B Cirrhosis after First Line Therapy)
- Hepatocellular Carcinoma

Checkmate 040 Subgroup: Cabozantinib + Nivolumab ± Ipilimumab (First line and Previously Treated Advanced HCC)
- Hepatocellular Carcinoma

Cabozantinib (Metastatic, Metastatic CRC)
- Colorectal Cancer

Cabozantinib + Pembrolizumab (Advanced or Metastatic cancers in Gastro Esophageal Adenocarcinoma)
- Gastric or Gastro-Esophageal Cancer

COSMIC-310: Cabozantinib + Atezolizumab vs. Sorafenib vs. Cabozantinib (First line Advanced HCC)
- Hepatocellular Carcinoma

Thyroid Cancer

COSMIC-035: Cabozantinib + Ansofaftumab (DTC)
- Differentiated Thyroid Cancer

Cabozantinib (Locally Ave Metastatic DTC)
- Differentiated Thyroid Cancer

Lung Cancer

COSMIC-026: Cabozantinib (NSCLC)
- Non-Small Cell Lung Cancer

COSMIC-030: Cabozantinib + Atezolizumab (NSCLC)
- Non-Small Cell Lung Cancer

Cabozantinib vs. Cabozantinib + Nivolumab vs. Nivolumab (Previously Treated Non Squamous NSCLC)
- Non-Small Cell Lung Cancer

Cabozantinib (Molecular Alterations in MET, RET, RET, AXL, or NTRK)
- Non-Small Cell Lung Cancer

Nivolumab vs. Cabozantinib + Nivolumab vs. Cabozantinib + Nivolumab + Ipilimumab (NSCLC)
- Non-Small Cell Lung Cancer

CONTACT-01: Cabozantinib + Atezolizumab vs. Docetaxel (Metastatic Non Squamous NSCLC)
- Non-Small Cell Lung Cancer

Gynecologic Cancers

COSMIC-039: Cabozantinib + Atezolizumab (vs. Chemo (Uterine & Ovarian Cancer))
- Breast Cancer / Ovarian Cancer / Endometrial Cancer

Nivolumab + Cabozantinib (Advanced or Metastatic EC)
- Endometrial Cancer

Neuroendocrine Tumors (NET) & Carcinoid

Cabozantinib (Neuroendocrine Neoplasms)
- NET & Carcinoid

Cabozantinib + Nivolumab + Ipilimumab (Poorly Differentiated Neuroendocrine Carcinoma)
- NET & Carcinoid

Cabozantinib + Nivolumab (Advanced Carcinoid Tumors)
- NET & Carcinoid

Cabozantinib (Advanced Pancreatic NET & Advanced Carcinoid)
- NET & Carcinoid

CABINET: Cabozantinib vs. Placebo (Advanced Neuroendocrine Tumors After Progression on Sunitinib)
- NET & Carcinoid

Adrenocortical Carcinoma

Cabozantinib (Metastatic Pheochromocytomas and Paragangliomas)
- Adrenal Tumors

Cabozantinib (Metastatic Adrenocortical Carcinoma)
- Adrenal Tumors

Sarcoma

Cabozantinib + Nivolumab (Taxane Pre-Treated) vs. Pazitinib + Nivolumab (Taxane Pre-Treated) (Angiosarcoma)
- Sarcoma

Cabozantinib ± PD-1 and CTLA-4 Inhibition (Metastatic Soft Tissue Sarcoma)
- Sarcoma

Cabozantinib + Radiation Therapy (Sarcoma of the Extremities)
- Sarcoma

Cabozantinib + Temozolomide (Leiomyosarcoma of Uterus and Soft Tissue Sarcomas)
- Sarcoma

Cabozantinib vs. Placebo (High Grade Uterine Sarcoma)
- Sarcoma

Cabozantinib (Metastatic, Soft Tissue Sarcoma)
- Sarcoma

Neuroforoma

Cabozantinib in Plexiform Neurofibromas
- Neuroforoma

Gastroesophageal Cancer

CABELLA: Cabozantinib + Durvalumab (Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma)
- Gastroesophageal Cancer / Esophageal Cancer

COSMIC-029: Cabozantinib + Atezolizumab (HCC & Gastroesophageal cancer adenocarcinoma)
- Gastroesophageal Cancer

Head and Neck Cancer

Cabozantinib + Cetuximab (Metastatic, Metastatic Squamous Cell Carcinoma)
- Squamous Cell Carcinoma

COSMIC-029: Cabozantinib + Atezolizumab (Head and Neck Cancer)
- Head and Neck Cancer

Cabozantinib + Pembrolizumab (Metastatic, Metastatic Squamous Cell Carcinoma)
- Squamous Cell Carcinoma

Melanoma

Cabozantinib + Pembrolizumab (Metastatic, Metastatic Melanoma)
- Melanoma

Cabozantinib + Nivolumab + Ipilimumab (Unresectable Advanced Melanoma)
- Melanoma

Pediatric Cancer

Cabozantinib + Nivolumab Adol
- Pediatric Multiple Tumor Types

Cabotinibs: Cabozantinib (High-risk Pediatric Solid Tumors)
- Pediatric Multiple Tumor Types

Cabozantinib in Plexiform Neurofibromas
- Pediatric Neurofibroma

CABONC: Cabozantinib (Combined Cohort and Cuing Dynamics, Pediatric Ext)
- Pediatric Sarcoma

Cabozantinib (Refractory Recurring, Other Tumor, Other Solid Tumors)
- Pediatric Multiple Tumor Types

Other Partnered Compounds

We are also advancing cancer treatment through collaborations.

LEARN MORE >

© Exelixis, Inc. 2022 Ethics & Compliance | Privacy | Terms of Use